List view / Grid view
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure.
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
Explore current insights into the clinical possibilities posed by organoids and delve into short and long-term prospects for therapeutic screening and personalised regenerative medicine in this whitepaper.
Join Malvern Panalytical for a 15-minute webinar to learn about ex vivo inflammasome slice assays for neuroinflammation discovery.
Discover key target cells for immunotherapy, how cells and processes can be assessed in vitro and approaches for selecting the most appropriate assay.
CIRM grant will fund novel gene therapy that aims for single lifelong treatment of Friedreich’s ataxia, a progressive neuromuscular disorder; a second CIRM grant will advance efforts to leverage UC San Diego research on another rare disease
Discover everything pharmaceutical scientists need to know about solid form characterisation, starting with API selection.
Sino Biological announced the formal signing of a lease with Hines and initiation of construction on its new Centre for Bioprocessing (C4B) at its Levit Green facility in Houston, US.
Biovac signs deal with IVI to develop and manufacture oral cholera vaccine (OCV) for African and global markets.
Discover how Malvern Panalytical’s combination of analytical instrumentation and research services can take particle size analysis to the next level.
This Malvern Panalytical guide explores the use of Xray powder diffraction (XRPD) as a powerful tool to develop and improve pharmaceutical formulation.
The College of American Pathologists has given accreditation to Altasciences’ clinical site in Los Angeles, California.
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
A report has found that increased investment in drug discovery will help the demand for personalised medicine, encouraging the growth of the liquid handling market.
Incannex Healthcare has completed a pre-IND meeting with the FDA for IHL-216A, a drug product for treatment of traumatic brain injury.
